Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.5 USD | -0.59% | +3.62% | +34.25% |
Financials (USD)
Sales 2024 * | 1.82B | Sales 2025 * | 2.95B | Capitalization | 12.15B |
---|---|---|---|---|---|
Net income 2024 * | 222M | Net income 2025 * | 1.08B | EV / Sales 2024 * | 5.97 x |
Net cash position 2024 * | 1.27B | Net cash position 2025 * | 2.39B | EV / Sales 2025 * | 3.31 x |
P/E ratio 2024 * |
51.3
x | P/E ratio 2025 * |
11.5
x | Employees | 1,314 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.22% |
Latest transcript on Sarepta Therapeutics, Inc.
1 day | -0.59% | ||
1 week | +3.62% | ||
Current month | +1.22% | ||
1 month | -5.85% | ||
3 months | +32.40% | ||
6 months | +4.75% | ||
Current year | +34.25% |
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 1 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 129.5 | -0.59% | 811,626 |
24-03-27 | 130.2 | +1.54% | 592,604 |
24-03-26 | 128.2 | +0.24% | 530,108 |
24-03-25 | 127.9 | +0.31% | 396,054 |
24-03-22 | 127.5 | +2.08% | 628,292 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.25% | 12.15B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
-6.78% | 10.2B |